- Home
- WPC vs RPRX Comparison
WPC vs RPRX Comparison
Compare WPC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPC
- RPRX
- Stock Information
- Founded
- WPC 1973
- RPRX 1996
- Country
- WPC United States
- RPRX United States
- Employees
- WPC N/A
- RPRX N/A
- Industry
- WPC Real Estate Investment Trusts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- WPC Real Estate
- RPRX Health Care
- Exchange
- WPC Nasdaq
- RPRX Nasdaq
- Market Cap
- WPC 12.8B
- RPRX 14.2B
- IPO Year
- WPC 1998
- RPRX 2020
- Fundamental
- Price
- WPC $62.99
- RPRX $31.17
- Analyst Decision
- WPC Hold
- RPRX Strong Buy
- Analyst Count
- WPC 12
- RPRX 5
- Target Price
- WPC $62.82
- RPRX $41.60
- AVG Volume (30 Days)
- WPC 1.5M
- RPRX 4.6M
- Earning Date
- WPC 04-29-2025
- RPRX 05-08-2025
- Dividend Yield
- WPC 5.58%
- RPRX 2.82%
- EPS Growth
- WPC N/A
- RPRX N/A
- EPS
- WPC 2.09
- RPRX 1.91
- Revenue
- WPC $1,576,386,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- WPC $4.86
- RPRX $34.04
- Revenue Next Year
- WPC $5.08
- RPRX $6.10
- P/E Ratio
- WPC $30.16
- RPRX $16.30
- Revenue Growth
- WPC N/A
- RPRX N/A
- 52 Week Low
- WPC $52.91
- RPRX $24.05
- 52 Week High
- WPC $66.10
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- WPC 57.84
- RPRX 34.22
- Support Level
- WPC $62.00
- RPRX $30.64
- Resistance Level
- WPC $64.00
- RPRX $34.14
- Average True Range (ATR)
- WPC 1.16
- RPRX 0.74
- MACD
- WPC -0.12
- RPRX -0.33
- Stochastic Oscillator
- WPC 69.85
- RPRX 15.14
About WPC W. P. Carey Inc. REIT
W.P. Carey Inc is a real estate investment trust principally involved in the ownership of properties located in the U.S., Western Europe, and Northern Europe. W.P. Carey organizes its operations into Real Estate and Investment Management segments. The vast majority of the company's income is derived from its Real Estate division in the form of lease revenue from long-term agreements with companies. W.P. Carey's real estate portfolio is primarily comprised of single-tenant office, industrial, warehouse, and retail facilities located around the world. majority of the company's revenue comes from properties in the USA. Its Investment Management unit generates revenue from providing real estate advisory and portfolio management services to other REITs.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.